

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :  A61K 37/02	A2	(11) International Publication Number: WO 94/06454 (43) International Publication Date: 31 March 1994 (31.03.94)
<p>(21) International Application Number: PCT/US93/08486</p> <p>(22) International Filing Date: 9 September 1993 (09.09.93)</p> <p>(30) Priority data: 07/943,369 9 September 1992 (09.09.92) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 07/943,369 (CIP) Filed on 9 September 1992 (09.09.92)</p> <p>(71) Applicants (for all designated States except US): SYNERGEN, INC. [US/US]; 1885 33rd Street, Boulder, CO 80301 (US). THE UNITED STATES OF AMERICA [US/US]; Dept. of Health &amp; Human Services, Office of Technology Transfer, Box OTT, Bethesda, MD 20892 (US).</p>	<p>(72) Inventors; and (75) Inventors/Applicants (for US only): EISENBERG, Stephen [US/US]; 5664 Pennsylvania Place, Boulder, CO 80303 (US). WAHL, Sharon, M. [US/US]; 17121 Longdraft Road, Gaithersburg, MD 20878 (US). THOMPSON, Robert, C. [GB/US]; 1820 Lehigh Street, Boulder, CO 80303 (US).</p> <p>(74) Agents: KOIVUNIEMI, Paul, K. et al.; Synergen, Inc., 1885 33rd Street, Boulder, CO 80301 (US).</p> <p>(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> Without international search report and to be republished upon receipt of that report.</p>	

(54) Title: INHIBITION OF RETROVIRUS INFECTION

REVERSE TRANSCRIPTASE  
(cpm  $\times 10^3/15 \mu\text{l}$ )



(57) Abstract

Methods and pharmaceutical compositions are provided to prevent retroviral infections of host cells. More particularly, the invention relates to prevention of HIV infection of human cells by serine leukocyte protease inhibitor (SLPI).

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LJ	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

## INHIBITION OF RETROVIRUS INFECTION

This invention relates to the field of the treatment of retroviral infections and, more particularly, to the treatment of human immunodeficiency virus (HIV) infection and associated disease, including acquired immune deficiency syndrome (AIDS).

### Background of the Invention

Retroviral agents have been implicated in a number of diseases, including cancer, autoimmune disease and AIDS. Human immunodeficiency virus (HIV) infection causes chronic progressive depletion of CD4<sup>+</sup> T lymphocytes (CD4<sup>+</sup> cells) and infection of macrophages, resulting in acquired immune deficiency syndrome. Currently zidovudine (AZT), an analogue of thymidine, is the primary anti-viral drug used in the treatment of HIV infection, although two other agents with a similar mechanism of action, dideoxyinosine (ddI) and dideoxycytosine (ddC), are also used. Colley, T.P. et al., New Engl. J. Med. (1990) 322:1340-45; Fischl, M.A., et al., New Engl. J. Med. (1987) 317:185-91. These agents are effective in inhibiting viral replication, and can stabilize the CD4<sup>+</sup> cell levels, but they are unable to eliminate one of the major viral reservoirs, HIV infected macrophages. Gartner, S., et al., Science (1986) 233:215-19. Severe toxicity, particularly involving HIV host bone marrow is also associated with higher doses of AZT treatment, and the beneficial effects of the drug in AIDS patients diminishes after prolonged therapy; HIV strains resistant to AZT also have been observed in treated patients. These findings have prompted the search for alternative drugs for the treatment of HIV infection, particularly agents with a different mechanism of action.

Human immunodeficiency virus type 1 (HIV-1), a retrovirus, is the etiologic cause of AIDS. The HIV-1 envelope glycoprotein, gp120, specifically binds to the CD4 receptor on T lymphocytes and on monocytes and macrophages. Although infection of T lymphocytes requires cellular proliferation and DNA synthesis, productive infection of monocytes can occur

independently of cellular DNA synthesis (Weinberg, J.B., et al., (1991) J. Exp. Med. 174:1477-82). When HIV-1 infects activated CD4<sup>+</sup> lymphocytes, it is lethal, but infected monocytes are relatively resistant to destruction by the virus. Consequently, these cells, once infected with HIV-1, serve as long-lived reservoirs of the virus. Not only are these cells a source of replicating virus, but their virally-mediated dysfunction may contribute to increased susceptibility to opportunistic infections that are the hallmark of AIDS.

Because monocyte-macrophages serve as reservoirs for HIV-1, selective targeting of this population, in addition to T lymphocytes, warrants further consideration (Finberg, R.W., et al., Science 252:1703-05, 1991. Early reports from Fox's group (JADA 118:709-711, 1989) indicated that a component of human saliva blocks HIV replication. More recently, Hattori (FEBS Lett. 248:48-52, 1989) showed that an inhibitor of tryptase (a trypsin-like enzyme) can inhibit syncytia formation of T-cells induced by HIV.

In exploring various potential modulators of HIV-1 infection, we have recently identified an endogenous source of inhibitory activity which retards HIV-1 infection and/or replication.

The factor responsible for the antiviral activity is serine leukocyte protease inhibitor (SLPI). SLPI is a potent inhibitor of human leukocyte elastase and cathepsin G and of human trypsin, and has been purified from parotid secretions (Thompson, R.C. and K. Ohlsson, (1986) Proc. Natl. Acad. Sci. USA, 83:6692-96; and U.S. Patent No. 4,760,130, both of which are incorporated herein by reference). SLPI is now available through production by recombinant DNA techniques; U.S. patent application No. 07/712,354, filed June 7, 1991, PCT application No. WO86/03519, filed December 4, 1985, and European patent application 85 905 953.7, filed December 4, 1985, each of which are incorporated herein by reference).

The ability of SLPI and/or its derivatives and analogs to block HIV-1 infection and/or replication can provide the basis for therapeutic intervention in HIV-1 infection.

### Summary of the Invention

The present invention provides novel methods for preventing or treating retroviral infections of mammalian cells, particularly preventing infection of human cells with human immunodeficiency virus (HIV) and associated diseases, including acquired immune deficiency syndrome (AIDS).

Included within the scope of this invention are pharmaceutical compositions for treating retroviral infections, particularly HIV infections in a human, comprising serine leukocyte protease inhibitor (SLPI), or an analog or derivative thereof, and a pharmaceutically acceptable carrier.

The invention also includes a method for treating HIV infections in a human cell comprising administering thereto an effective amount of SLPI or an analog or derivative thereof.

### Brief Description of the Figures

Figure 1. SLPI blocks HIV replication in monocytes in a dose-dependent manner. Elutriated human monocytes were plated and exposed to HIV  $\pm$  SLPI for one hour at 37°C, washed, and incubated at 37°C, drawing off supernatants and adding fresh medium every four days. The EC<sub>50</sub> for this experiment was <0.1  $\mu$ g/ml (8.5 nM) with complete inhibition at 10  $\mu$ g/ml (850 nM).

Figure 2. The SLPI inhibitory effect is long-lasting. At the 18-day time point, HIV is still 90% inhibited.

### Detailed Description of the Invention

The present invention provides methods for preventing retrovirus, particularly HIV infection of mammalian cells, particularly human cells, and associated diseases, including acquired immune deficiency syndrome (AIDS).

The term "pharmaceutically acceptable carrier" as used herein means a non-toxic, generally inert vehicle for the active ingredient, which does not adversely affect the ingredient or the patient to whom the formulation is administered.

The term "effective amount" as used herein means a pre-determined amount of SLPI, or an analog or derivative thereof, sufficient to be effective against HIV in vivo.

According to the present invention, retroviral infections are treated by administering anti-retroviral agents in doses sufficient to diminish the effects of such infection. Retroviral infections are implicated in a number of diseases, including but not limited to cancer, autoimmune disease, and acquired immune deficiency syndrome. Human immunodeficiency virus infection is of particular interest according to the present invention.

A variety of anti-retroviral agents are known in the art. Most of these inhibit the activity of retroviral reverse transcriptase and include zidovudine (AZT), an analogue of thymidine, dideoxyinosine (ddI), and dideoxycytosine (ddC). Zidovudine is the primary anti-viral drug used in the treatment of HIV infection. Anti-retroviral agents are generally efficacious in a dose ranging from about 50 mg/day to about 1000 mg/day, more particularly from about 100 mg/day to about 500 mg/day, and in the case of zidovudine, specifically about 300 mg/day to about 500 mg/day. These agents are generally administered in oral formulations.

The protease inhibitors used in this invention can be prepared by means well known to those skilled in the art (see, e.g., U.S. Patent No. 4,760,130; European patent application 85 905 953.7, PCT application WO86/03519, and U.S. patent application 07/712,354, supra).

The present invention relates to protease inhibitors which have been isolated in a purified form. Preferably, the serine protease inhibitors of the present invention are single-polypeptide-chain proteins which are substantially homologous to, and most preferably biologically equivalent to, the native serine protease inhibitor isolated from human parotid secretions. The native serine protease inhibitor is also referred to as the native parotid inhibitor. By "biologically equivalent" as used throughout the specification and claims, is meant that the compositions are capable of inhibiting the monocyte-derived protease that is inhibited by SLPI, but not necessarily to the same degree. By "derivatives" as used throughout the ensuing specification and claims, is meant a

degree of amino acid homology to the native parotid inhibitor, preferably in excess of 40%, most preferably in excess of 50%, with a particularly preferred group of proteins being in excess of 60% homologous with the native parotid inhibitor. The percentage homology, as above described, is calculated as the percentage of the components found in the smaller of the two sequences that may also be found in the larger of the two sequences, a component being understood as a sequence of four, contiguous amino acids.

One useful SLPI derivative is CLPI, a truncated SLPI molecule having only the last 60 amino acids of the native parotid inhibitor. These 60 amino acids are:

Leu Asp Pro Val Asp Thr Pro Asn Pro Thr Arg Arg Lys  
Pro Gly Lys Cys Pro Val Thr Tyr Gly Gln Cys Leu Met  
Leu Asn Pro Pro Asn Phe Cys Glu Met Asp Gly Gln Cys  
Lys Arg Asp Leu Lys Cys Cys Met Gly Met Cys Gly Lys  
Ser Cys Val Ser Pro Val Lys Ala.

The following nucleotide sequence has been used to encode the above 60 amino acid molecule:

CTG GAT CCT GTT GAC ACC CCA ACA CCA ACA AGG AGG AAG  
CCT GGG AAG TGC CCA GTG ACT TAT GGC CAA TGT TTG ATG  
CCT AAC CCC CCC AAT TTC TGT GAG ATG GAT GGC CAG TGC  
AAG CGT GAC TTG AAG TGT TGC ATG GGC ATG TGT GGG AAA  
TCC TGC GTT TCC CCT GTG AAA GCT.

CLPI has been constructed by deleting from the SLPI gene the signal sequence and the nucleotides corresponding to the first 47 amino acids of the mature SLPI protein as described in U.S. patent application 07/712,354. CLPI can also be made by the method of Example 8 described in both PCT application WO86/03519 and European patent application 85 905 953.7. Although Example 8 in these two applications recites a method of making SLPI, this method can also be used to make CLPI. CLPI can be used to generate antibodies useful in purifying SLPI. Antibodies can be produced, for example, by the methods discussed in E. Harlow & D. Lane, Antibodies: A Laboratory Manual, pp. 92-114 (Cold Springs Harbor Laboratory, 1988).

By "analogs" as used herein, is meant any compound, including, for example, small organic compounds, that are functionally biologically equivalent to SLPI in inhibiting HIV infection. Such derivatives and analogs can be isolated by means well known to those skilled in the art, including using monocyte cells to screen for compounds that prevent SLPI from binding thereto. Analogs may also include specific SLPI muteins that have at least equivalent, and in some cases, greater activity than the native protein. Particularly useful SLPI muteins include substitution of the following amino acids at the residue position enumerated: Gly 20, Gly 72, Val 72, and Phe 72.

CLPI muteins are also within the scope of the invention. CLPI muteins which correspond to the SLPI muteins Gly 72, Val 72, and Phe 72 are herein referred to as Gly 25, Val 25, and Phe 25. Some contemplated CLPI muteins have the following amino acid sequence:

Leu Asp Pro Val Asp Thr Pro Asn Pro Thr Arg Arg Lys  
 Pro Gly Lys Cys Pro Val Thr Tyr Gly Gln Cys R<sub>8</sub> R<sub>3</sub>  
 R<sub>9</sub> Asn Pro Pro Asn Phe Cys Glu R<sub>4</sub> Asp Gly Gln Cys  
 Lys Arg Asp Leu Lys Cys Cys R<sub>5</sub> Gly R<sub>6</sub> Cys Gly Lys  
 Ser Cys Val Ser Pro Val Lys R<sub>7</sub>

wherein R<sub>7</sub> is alanine, and R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> are the same or different amino acids and one or more of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> may be methionine, valine, alanine, phenylalanine, tyrosine, tryptophan, lysine, glycine, or arginine. Analogs also include, for example, PEGylated forms of SLPI or CLPI which may have improved therapeutic characteristics over the native SLPI protein. Muteins which may be suitable for PEGylation include those having a cysteine residue at positions 13, 23, 52, 58, 68, and/or 75 of SLPI and at the corresponding sites 5, 11, 21, and 28 in CLPI. Preparation of cysteine muteins for PEGylation is described in PCT application WO 92/16221, filed March 13, 1992, which is specifically incorporated herein by reference. A useful step in mutein production can include a refolding step in which cysteine is added to the solution containing the protein. The cysteine can aid in refolding and can bond to the substituted free cysteine in the mutein. One may also isolate



from monocytes the SLPI inhibitable protein (SIP) from human monocyte cells using standard biochemical techniques well known to those skilled in the art and purify proteins having proteolytic activity which is inhibited by SLPI. After  
5 purifying the protein (and, if necessary, sequencing it, cloning its gene, and expressing it in host cells, i.e., recombinantly producing SIP), one can screen for inhibitors of SIP by means well known to those skilled in the art. Alternatively, one can determine its structure and design inhibitors therefrom, also  
10 by means well known to those skilled in the art.

When SLPI, or an analog or derivative thereof, is used to combat HIV infections in a human, the compound can be administered orally or parenterally, in a vehicle comprising one or more pharmaceutically acceptable carriers, the proportion of  
15 which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard biological practice. For oral administration, SLPI, or analog or derivative thereof, can be formulated in unit dosage forms such as capsules or tablets each containing a predetermined amount  
20 of the active ingredient, ranging from about 10 to 1000 mg, more preferably 10-200 mg per day per patient, even more preferably 20-200 mg per day per patient, in a pharmaceutically acceptable carrier.

For parenteral administration, the SLPI or analog or derivative thereof, is administered by either intravenous,  
25 subcutaneous or intramuscular injection, in compositions with pharmaceutically acceptable vehicles or carriers. For administration by injection, it is preferred to use the compound in solution in a sterile aqueous vehicle which may also contain  
30 other solutes such as buffers or preservatives as well as sufficient quantities of pharmaceutically acceptable salts or of glucose to make the solution isotonic. Subcutaneous injection is the preferred route of administration. Dosages are essentially the same as those set forth above for oral  
35 administration.

Suitable vehicles or carriers for the above noted formulations can be found in standard pharmaceutical texts,

e.g., in "Remington's Pharmaceutical Sciences," 16th ed, Mack Publishing Company, Easton, PA, 1980, and incorporated herein by reference.

5       The dosage of the compound will vary with the form of  
administration and the particular active agent chosen.  
Furthermore, it will vary with the particular patient or host  
(including mammals, including humans) under treatment.  
Generally, treatment is initiated with small dosages  
substantially less than the optimum dose of the compound.  
10    Thereafter, the dosage is increased by small increments until  
the optimum effect under the circumstances is reached. In  
general, the compound is most desirably administered at a  
concentration level that will generally afford antivirally  
effective results without causing any harmful or deleterious  
15    side effects. It is desirable to maintain a blood level of the  
compound at a level sufficient to inhibit retrovirus infection  
of the host cell. This can be estimated by assaying the amount  
of compound that is effective in preventing retroviral infection  
of host cells, e.g., HIV into monocytes, in vitro, and then,  
20    using standard pharmacokinetic techniques, determining the  
amount of compound required to keep plasma level at the same  
inhibitory level, or up to 10-100 times more.

Although the formulations disclosed hereinabove are  
effective and relatively safe medications for treating HIV  
25    infections, the possible concurrent administration of these  
formulations with other antiviral medications or agents to  
obtain beneficial results is not excluded. Such other antiviral  
medications or agents include soluble CD4, zidovudine,  
dideoxycytidine, phosphonoformate, ribavirin, antiviral  
30    interferons (e.g. alpha -interferon or interleukin-2) or aerosol  
pentamidine.

The invention is exemplified by the following illustrative  
examples:

35    Example 1. Peripheral blood monocytes (PBM) were isolated  
from healthy donors by elutriation, plated in culture dishes,  
and incubated for several days. SLPI was mixed with HIV (Bal)  
and applied to PBM for one hour at 37°C. Cells were washed and

incubated for additional time, with media changes and reverse transcriptase determinations on supernatants done every three days. We found that SLPI effectively blocks HIV replication at a concentration of 1  $\mu\text{g/ml}$  (Figure 1). At concentrations  $\leq 20$   $\mu\text{g/ml}$ , SLPI inhibition is diminished. The inhibitory effect is long lasting, with significant inhibition seen out to 18 days (Figure 2).

Example 2. PBM were plated and incubated as in Example 1. SLPI was applied to cells for about one hour, cells were then washed, and treated with HIV. Medium was changed and assays done as in Example 1. We found that SLPI was more effective at blocking HIV when cells were pretreated with SLPI than when cells were treated with a mix of SLPI and HIV.

Example 3. We have also demonstrated using essentially the same protocol as in Example 1, but substituting T-cells for monocytes, that SLPI is effective in inhibiting HIV replication in T-cells.

Example 4. A human T-lymphocytic cell line (H-9) was maintained in suspension culture in RPMI 1640 with 10% fetal calf serum (FCS) and 200 micrograms per liter gentamicin. SLPI was added to the culture medium at a final concentration of 100 micrograms per milliliter. After 24 hours, cells were washed, inoculated for four hours with HIV strain IIIB, washed again, and resuspended at a density of 500,000 cells per milliliter. Media was supplemented and maintained with SLPI at a final concentration of 100 micrograms per milliliter immediately after resuspension (T=0) or 2 days after resuspension (T=2). Culture supernatant was collected and cultures were fed every 2 days. Supernatant collected 8 days after infection was assayed for reverse transcriptase activity by measuring uptake of tritiated thymidine onto a poly(rA)-oligo(dT) template.

As shown in Table 1, in SLPI pretreated cells, SLPI inhibited viral replication by approximately 62% and 54% when added immediately after infection and 2 days after infection, respectively.

TABLE 1

## SLPI PRE-TREATED CELLS

	Negative Control	Positive Control	T = 0	T = 2
RT Activity (mean cpm)	955	86,205	32,594	39,554
Standard Deviation	± 330	± 9,676	± 7,220	± 8,737

Example 5. The experiment was performed as described in Example 4 except that 1000-fold concentrated HIV strain IIIB was incubated with 100 micrograms per milliliter SLPI for 6 hours on ice prior to inoculation. This HIV/SLPI mixture was diluted 1000-fold prior to the four hour inoculation.

As shown in Table 2, using SLPI pre-treated virus and cells, SLPI inhibited viral replication by approximately 64% and 26% when added immediately after infection and 2 days after infection, respectively.

TABLE 2

## SLPI PRE-TREATED VIRUS AND CELLS

	Negative Control	Positive Control	T = 0	T = 2
RT Activity (mean cpm)	2,889	59,004	20,676	43,432
Standard Deviation	± 565	± 10,988	± 4,111	± 14,982

Example 6. The experiment was performed as in Example 5 except that cells were clean, i.e. not cultured with SLPI prior to inoculation. Using clean cells and SLPI pre-treated virus, SLPI inhibited viral replication by approximately 59% and 32% when added immediately after infection and 2 days after infection, respectively (Table 3).

**TABLE 3**  
**SLPI PRE-TREATED VIRUS**

	Negative Control	Positive Control	T = 0	T = 2
RT Activity (mean cpm)	4,763	70,076	28,383	47,436
Standard Deviation	± 1,698	± 15,803	± 5,520	± 11,679

Example 7. The experiment was performed as in Examples 4-6 except that neither cells nor virus were exposed to SLPI prior to inoculation. Using clean cells and clean virus, SLPI inhibited viral replication by approximately 50% and 42% when added immediately after infection and 2 days after infection, respectively (Table 4). Table 5 shows the reverse transcriptase activity which was present in culture supernatant assayed 4, 6, and 8 days after infection.

**TABLE 4**  
**CLEAN CELLS AND VIRUS**

	Negative Control	Positive Control	T = 0	T = 2
RT Activity (mean cpm)	531	79,356	38,969	46,004
Standard Deviation	± 186	± 17,497	± 7,700	± 8,492

**TABLE 5**  
**CLEAN CELLS AND VIRUS**

	Negative	Positive	T = 0	T = 2
Day 4 (mean cpm)	435	1,556	797	1,287
Standard Deviation	± 85	± 300	± 222	± 204
Day 6 (mean cpm)	952	72,085	15,846	41,240
Standard Deviation	± 715	± 12,219	± 5,644	± 14,542
Day 8 (mean cpm)	1,519	13,853	7,617	11,946
Standard Deviation	± 475	± 3,458	± 3,031	± 2,889

Example 8. The effect of different SLPI muteins on viral replication was also investigated. Clean H-9 cells were incubated with clean virus for 4 hours as in Example 7. After washing, cells were resuspended at a density of 500,000 cells per milliliter in media containing 30 micrograms per milliliter SLPI or the SLPI muteins shown in Table 6. Culture supernatant was assayed for reverse transcriptase activity 8 days later (Table 6).

**TABLE 6**

	Negative Control	Positive Control	Wild Type	Gly 20	Gly 72	Val 72	Lys 72	Phe 72
RT Activity (mean cpm)	4,815	55,126	39,323	39,387	40,549	36,077	52,239	8,384
Standard Deviation	± 2,849	± 6,637	±10,933	±11,143	± 3,537	± 7,859	± 5,863	±1,924

Example 9. The experiment was performed as in Example 8 except that after inoculation, cells were resuspended in media containing 100 micrograms per milliliter SLPI or the Phe 72 mutein. Culture supernatant was assayed for reverse transcriptase activity 2, 4, 6, 8, and 10 days post-infection (Table 7). Tables 6 and 7 show that the effect of the Phe-72 mutein was particularly pronounced.

TABLE 7

	Negative	Positive	SLPI	PHE-72
Day 2 (mean cpm)		1,386	995	897
Standard Deviation		± 914	± 246	± 472
Day 4 (mean cpm)		1,356	1,087	1,380
Standard Deviation		± 370	± 414	± 442
Day 6 (mean cpm)	1,142	2,103	1,526	748
Standard Deviation	± 389	± 498	± 508	± 243
Day 8 (mean cpm)		77,931	25,241	3,491
Standard Deviation		± 9,779	± 8,399	± 1,086
Day 10 (mean cpm)		21,431	12,499	2,239
Standard Deviation		± 1,890	± 3,495	± 444

Example 10. To determine the effect of SLPI alone, H-9 cell proliferation was evaluated by thymidine incorporation assays using 200,000 H-9 cells cultured with 100 micrograms per milliliter SLPI and without SLPI. Cultures were pulsed with media containing 2.5 microcuries of tritiated thymidine at day 0, 1, and 2; incorporated counts were measured on day 1, 2, and 3. As shown in Table 8, SLPI is not toxic to these cells.

TABLE 8

RT ACTIVITY (mean cpm)

H-9 PROLIFERATION

	Day 1	Day 2	Day 3
Control (- SLPI)	20,860	67,401	53,326
Standard Deviation	± 581	± 2,529	± 3,783
+ SLPI 100 µg/ml	20,437	61,892	54,592
Standard Deviation	± 1,503	± 216	± 2,781

Example 11. We also investigated inhibition of viral production from chronically infected cells using the

promonocytic cell line U1. Suspension cultures of U1 were maintained in RPMI with 10% FCS and 200 micrograms per liter gentamicin. Cells were harvested, washed, and suspended at a density of 2.5 million cells per milliliter. Suspended cells were cultured overnight in media containing 100 or 200 micrograms per milliliter SLPI or media alone. Virus was induced by addition of 13-phorbol-12-myristate acetate (PMA) to a final concentration of 1 micromolar. After 48 hours, cell culture supernatant was assayed for reverse transcriptase activity as in Examples 4-9. As shown in Table 9, SLPI significantly inhibited viral production from these chronically infected cells.

TABLE 9

	- PMA - SLPI	- PMA + SLPI (200 µg/ml)	+ PMA - SLPI	+ PMA + SLPI (200 µg/ml)	+ PMA + SLPI (100 µg/ml)
RT Activity (mean cpm)	1,052	994	5,052	2,864	2,648
Standard Deviation	± 352	± 447	±2,053	± 403	± 374

The foregoing description of the invention is exemplary for purposes of illustration and explanation. It should be understood that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, the following claims are intended to be interpreted to embrace all such modifications.



What is Claimed Is

1. A method for inhibiting retrovirus infection comprising administering to a host in need of such treatment an amount of serine leukocyte protease inhibitor, or analog or derivative thereof, (SLPI) sufficient to block infection of said host by said retrovirus.

2. The method according to claim 1, wherein the retrovirus is a human immunodeficiency deficiency virus (HIV).

3. The method according to claim 2, wherein the HIV is HIV-1.

4. A method for treating HIV infection comprising administering SLPI at a level and for a time sufficient to inhibit HIV infection of said host.

5. The method of claim 4 wherein SLPI is administered intraperitoneally.

6. The method of claim 4 wherein SLPI is administered intravenously.

7. The method of claim 4 wherein SLPI is administered subcutaneously.

8. The method of claim 1 wherein the host is a mammal.

9. The method according to claim 8, wherein the mammal is a human.

10. The method according to claim 9, wherein the retrovirus is a human immunodeficiency virus.

11. A method of inhibiting retrovirus infection comprising blocking the function of a host cell enzyme, which enzyme function is necessary for retrovirus infection of the cell.

12. The method according to claim 11, wherein the retrovirus is HIV.

13. The method according to claim 1, wherein the the SLPI analog or derivative is the SLPI Phe 72 mutein.

14. The method according to claim 1, wherein the SLPI analog or derivative is the SLPI Gly 20 mutein.

15. The method according to claim 1, wherein the SLPI analog or derivative is the SLPI Gly 72 mutein.

16. The method according to claim 1, wherein the SLPI analog or derivative is the SLPI Val 72 mutein.

17. The method according to claim 1, wherein the SLPI analog or derivative is the CLPI Phe 25 mutein.

18. The method according to claim 1, wherein the SLPI analog or derivative is the CLPI mutein Gly 25.

19. The method according to claim 1, wherein the SLPI analog or derivative is the CLPI Val 25 mutein.

20. An isolated serine protease inhibitor which inhibits chymotrypsin and elastase but does not inhibit trypsin.

21. The isolated protease inhibitor of claim 20 wherein the inhibitor has the following amino acid sequence:

Leu Asp Pro Val Asp Thr Pro Asn Pro Thr Arg Arg Lys  
Pro Gly Lys Cys Pro Val Thr Tyr Gly Gln Cys Leu Met  
Leu Asn Pro Pro Asn Phe Cys Glu Met Asp Gly Gln Cys  
Lys Arg Asp Leu Lys Cys Cys Met Gly Met Cys Gly Lys  
Ser Cys Val Ser Pro Val Lys Ala.

22. The isolated protease inhibitor of claim 20 wherein the inhibitor has the following amino acid sequence:

Leu Asp Pro Val Asp Thr Pro Asn Pro Thr Arg Arg Lys  
Pro Gly Lys Cys Pro Val Thr Tyr Gly Gln Cys R<sub>3</sub> R<sub>3</sub>  
R<sub>3</sub> Asn Pro Pro Asn Phe Cys Glu R<sub>4</sub> Asp Gly Gln Cys  
Lys Arg Asp Leu Lys Cys Cys R<sub>5</sub> Gly R<sub>6</sub> Cys Gly Lys  
Ser Cys Val Ser Pro Val Lys R<sub>7</sub>

wherein R<sub>7</sub> is alanine, and

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> are the same or different amino acids and are selected from the group consisting of methionine, valine, alanine, phenylalanine, tyrosine, tryptophan, lysine, glycine, and arginine.

23. The isolated protease inhibitor of claim 22, wherein R<sub>8</sub> is phenylalanine.

24. The isolated protease inhibitor of claim 22, wherein R<sub>8</sub> is glycine.

25. The isolated protease inhibitor of claim 22, wherein R8 is valine.

26. An isolated nucleic acid which encodes a serine protease inhibitor of claim 20.

27. The isolated nucleic acid of claim 26 which encodes a serine protease inhibitor having the following amino acid sequence:

Leu Asp Pro Val Asp Thr Pro Asn Pro Thr Arg Arg Lys  
Pro Gly Lys Cys Pro Val Thr Tyr Gly Gln Cys Leu Met  
Leu Asn Pro Pro Asn Phe Cys Glu Met Asp Gly Gln Cys  
Lys Arg Asp Leu Lys Cys Cys Met Gly Met Cys Gly Lys  
Ser Cys Val Ser Pro Val Lys Ala.

28. The isolated nucleic acid of claim 26 which encodes a serine protease inhibitor having the following amino acid sequence:

Leu Asp Pro Val Asp Thr Pro Asn Pro Thr Arg Arg Lys  
Pro Gly Lys Cys Pro Val Thr Tyr Gly Gln Cys R<sub>8</sub> R<sub>3</sub>  
R<sub>9</sub> Asn Pro Pro Asn Phe Cys Glu R<sub>4</sub> Asp Gly Gln Cys  
Lys Arg Asp Leu Lys Cys Cys R<sub>5</sub> Gly R<sub>6</sub> Cys Gly Lys  
Ser Cys Val Ser Pro Val Lys R<sub>7</sub>

wherein R7 is alanine, and

R3, R4, R5, R6, and R8 are the same or different amino acids and are selected from the group consisting of methionine, valine, alanine, phenylalanine, tyrosine, tryptophan, lysine, glycine, and arginine.

29. The isolated nucleic acid of claim 27, wherein said nucleic acid has the following nucleotide sequence:

CTG GAT CCT GTT GAC ACC CCA ACA CCA ACA AGG AGG AAG  
CCT GGG AAG TGC CCA GTG ACT TAT GGC CAA TGT TTG ATG  
CCT AAC CCC CCC AAT TTC TGT GAG ATG GAT GGC CAG TGC  
AAG CGT GAC TTG AAG TGT TGC ATG GGC ATG TGT GGG AAA  
TCC TGC GTT TCC CCT GTG AAA GCT.

30. A method for recombinant production of a serine protease inhibitor having at least one active site possessing serine protease inhibitory activity comprising:

(a) preparing a nucleic acid capable of directing a host organism to produce a protein comprising the amino acid sequence:

Leu Asp Pro Val Asp Thr Pro Asn Pro Thr Arg Arg Lys  
 Pro Gly Lys Cys Pro Val Thr Tyr Gly Gln Cys R<sub>8</sub> R<sub>3</sub> R<sub>9</sub>  
 Asn Pro Pro Asn Phe Cys Glu R<sub>4</sub> Asp Gly Gln Cys Lys  
 Arg Asp Leu Lys Cys Cys R<sub>5</sub> Gly R<sub>6</sub> Cys Gly Lys Ser Cys  
 Val Ser Pro Val Lys R<sub>7</sub>,

wherein

R<sub>7</sub> is alanine, and

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>8</sub>, and R<sub>9</sub> are the same or different and are selected from the group consisting of methionine, valine, alanine, phenylalanine, tyrosine, tryptophan, lysine, glycine and arginine.


(b) Cloning the nucleic acid into a vector capable of being transferred into and replicating in a host microorganism, such vector containing operational elements for the nucleic acid:

(c) Transferring the vector containing the nucleic acid and operational elements into a host microorganism capable of expressing the serine protease inhibitor;

(d) Culturing the host microorganism under conditions appropriate for amplification of the vector and expression of the inhibitor;


(e) Harvesting the inhibitor; and

(f) Permitting the inhibitor to assume an active tertiary structure whereby it possesses serine protease inhibitor activity.

**FIG. 1**

REVERSE TRANSCRIPTASE  
(cpm x 10<sup>3</sup>/15 μl)

SLPI (μg/ml)

**FIG. 2**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**